X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/02/2855618/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Endometrial-Cancer-with-Priority-Review-St.html
https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-neoshot-of-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-for-msi-hdmmr-colon-cancer-neoadjuvant-therapy-302099295.html
https://www.prnewswire.com/news-releases/innovent-and-xuanzhu-enter-into-clinical-trial-collaboration-investigating-combination-therapy-of-sintilimab-pd-1-inhibitor-and-a-novel-adc-candidate-for-advanced-solid-tumors-in-china-302022707.html
https://www.globenewswire.com//news-release/2023/12/13/2795176/0/en/HUTCHMED-Announces-that-it-has-Completed-Enrollment-of-a-Phase-II-III-Trial-of-Fruquintinib-in-Combination-with-Sintilimab-for-Advanced-Renal-Cell-Carcinoma-in-China.html
https://www.prnewswire.com/news-releases/innovent-announces-the-phase-3-orient-16-study-results-published-in-jama-evaluating-sintilimab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-gastric-or-gastroesophageal-junction-ggej-adenocarcinoma-302006814.html
https://www.globenewswire.com/news-release/2023/07/20/2707823/0/en/HUTCHMED-Receives-Breakthrough-Therapy-Designation-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-Treatment-of-Advanced-Endometrial-Cancer-and-Completes-Enrollment-of-Re.html
https://www.prnewswire.com/news-releases/innovent-and-remegen-enter-into-clinical-trial-collaboration-investigating-combination-therapy-of-tyvyt-sintilimab-injection-and-novel-adc-candidates-for-advanced-solid-tumors-in-china-301862538.html
https://www.pharmaceutical-technology.com/news/synlogic-synb1934-orphan-drug/
https://www.prnewswire.com/news-releases/the-china-nmpa-approves-tyvyt-sintilimab-injection-in-combination-with-bevacizumab-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-nsclc-who-progressed-after-egfr-tki-therapy-301819664.html
https://www.prnewswire.com/news-releases/innovent-updates-the-results-from-the-orient-31-study-of-sintilimab-plus-chemotherapy-with-or-without-bevacizumab-in-patients-with-egfr-tki-failed-egfr-mutated-non-squamous-non-small-cell-lung-cancer-in-the-lancet-respiratory-medi-301817766.html
https://www.prnewswire.com/news-releases/innovent-releases-final-analysis-results-of-orient-16-the-phase-3-study-of-sintilimab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-gastric-cancer-at-the-aacr-annual-meeting-2023-301798493.html
https://www.prnewswire.com/news-releases/innovent-presents-phase-ib-clinical-data-update-of-ibi110-anti-lag-3-monoclonal-antibody-at-the-2022-european-society-for-medical-oncology-immuno-oncology-congress-301698078.html
https://www.prnewswire.com/news-releases/innovent-announced-clinical-data-of-multiple-trials-will-be-presented-at-the-2022-esmo-io-and-ash-annual-meetings-301687463.html
https://www.globenewswire.com/news-release/2022/10/27/2542692/0/en/HUTCHMED-Initiates-a-Phase-II-III-Trial-of-Fruquintinib-in-Combination-with-Sintilimab-for-Advanced-Renal-Cell-Carcinoma-in-China.html
https://www.prnewswire.com/news-releases/innovents-sintilimab-plus-chemotherapy-demonstrated-pfs-benefit-in-patients-with-egfr-mutated-non-squamous-non-small-cell-lung-cancer-in-the-second-interim-analysis-results-of-the-orient-31-study-301619380.html
https://www.prnewswire.com/news-releases/innovent-and-laekna-jointly-announce-first-patient-dosed-with-three-drug-combination-in-a-phase-12-study-for-the-treatment-of-patients-with-solid-tumors-who-were-resistant-to-prior-anti-pd-1pd-l1-therapy-301596506.html
https://www.prnewswire.com/news-releases/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-injection-by-china-nmpa-in-combination-with-chemotherapy-as-first-line-treatment-for-esophageal-squamous-cell-carcinoma-301570972.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-lillyinnovent-lung-cancer-drug-2022-03-24/
https://endpts.com/with-all-eyes-on-chinese-only-oncology-data-coherus-and-junshi-uncork-win-for-pd-1-drug-in-esophageal-cancer/
https://endpts.com/breaking-fda-advisors-recommend-against-approving-eli-lillys-pd-1-casting-shadow-over-future-of-china-made-cancer-drugs/
https://endpts.com/after-lillys-sintilimab-shellacking-china-only-oncology-trials-are-facing-a-new-and-unfavorable-reality-at-the-fda/
https://www.biospace.com/article/innovent-and-eli-lilly-and-company-announced-final-clinical-results-and-biomarker-analysis-of-phase-ib-study-of-tyvyt-sintilimab-injection-plus-bevacizumab-biosimilar-injection-for-advanced-hepatocellular-carcinoma/
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-of-china-acceptance-of-a-supplemental-new-drug-application-for-tyvyt-sintilimab-injection-plus-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-non-small-cell-l-301450678.html
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-of-china-acceptance-of-a-supplemental-new-drug-application-for-tyvyt-sintilimab-injection-plus-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-non-small-cell-l-301450678.html
https://www.prnewswire.com/news-releases/innovent-releases-the-orient-31-phase-3-study-first-interim-analysis-results-of-sintilimab-plus-byvasda-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-who-p-301429490.html
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma-301416246.html
https://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/
https://trialsitenews.com/innovent-announces-sintilimab-met-primary-endpoint-at-interim-analysis-of-orient31-trial-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-with-prior-egfr-tki-treatment/
https://endpts.com/langer-ciechanover-godfather-the-latest-ai-upstart-ipsen-forges-446m-aml-development-pact/
https://www.prnewswire.com/news-releases/innovent-announces-orient-31-a-phase-3-study-of-sintilimab-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-with-prior-egfr-tki-treatment-has-met-primary-endpoint-301401773.html
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-chemotherapy-as-first-line-therapy-for-esophageal-squamous-cell-carcinoma-escc-301382590.html
https://endpts.com/exclusives-eli-lilly-out-to-crash-the-megablockbuster-pd-l1-party-with-disruptive-pricing-reveals-cancer-biotech-buyout/
https://www.prnewswire.com/news-releases/innovent-releases-interim-analysis-results-of-sintilimab-plus-chemotherapy-for-the-first-line-treatment-of-esophageal-squamous-cell-carcinoma-in-the-phase-3-orient-15-study-at-esmo-congress-2021-301379638.html
https://www.prnewswire.com/news-releases/innovent-to-present-new-data-on-sintilimab-and-other-molecules-at-the-european-society-for-medical-oncology-esmo-congress-2021-301364837.html
https://www.clinicaltrialsarena.com/news/innovents-sintilimab-meets-primary-goal-in-phase-iii-gastric-cancer-trial/
https://www.prnewswire.com/news-releases/inxmeds-in10018-receives-us-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer-301355503.html
https://www.prnewswire.com/news-releases/sintilimab-in-combination-with-chemotherapy-meets-overall-survival-primary-endpoint-in-the-global-phase-3-orient-15-study-for-the-first-line-treatment-of-esophageal-squamous-cell-carcinoma-301317929.html
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-tyvyt-sintilimab-injection-in-combination-with-byvasda-bevacizumab-injection-as-first-line-therapy-in-hepatocellular-carcinoma-hcc-301206595.html
https://www.prnewswire.com/news-releases/innovent-releases-phase-3-results-of-tyvyt-sintilimab-injection-in-combination-with-byvasda-bevacizumab-biosimilar-injection-as-first-line-treatment-in-patients-with-advanced-hepatocellular-carcinoma-hcc-at-esmo-asia-virtu-301178480.html
https://seekingalpha.com/news/3620325-innovent-bios-expanded-collaboration-lilly-for-tyvyt-now-effective
https://www.prnewswire.com/news-releases/innovent-announces-the-effectiveness-of-the-expanded-global-collaboration-with-lilly-on-tyvyt-sintilimab-injection-following-the-expiration-of-hsr-act-waiting-period-301146892.html
https://www.asiaone.com/business/tyvyt-sintilimab-injection-combination-byvasda-bevacizumab-injection-orient-32-study-met
https://www.prnewswire.com/news-releases/innovent-and-lilly-jointly-release-phase-3-results-of-tyvyt-sintilimab-injection-in-combination-with-gemzar-gemcitabine-and-platinum-chemotherapy-as-first-line-treatment-for-squamous-non-small-cell-lung-cancer-at-esmo-virtua-301134399.html
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-granted-marketing-approval-for-sulinno-adalimumab-injection-in-china-301123750.html#:~:text=Men's%20Interest-,Innovent%20Announces%20NMPA%20Granted%20Marketing%20Approval,%C2%AE%20(Adalimumab%20Injection)%20in%20China&text=Innovent%20Biologics%2C%20Inc.&text=SAN%20FRANCISCO%2C%20U.S.%20and%20SUZHOU,%2F%20%2D%2D%20Innovent%20Biologics%2C%20Inc.
https://www.biospace.com/article/releases/innovent-and-eli-lilly-announce-acceptance-of-a-supplemental-new-drug-application-of-tyvyt-sintilimab-injection-in-combination-with-gemcitabine-and-platinum-as-first-line-therapy-in-squamous-non-small-cell-lung-cancer-in-china/
https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-1b-clinical-trial-of-sintilimab-plus-surufatinib-in-advanced-malignancies-in-china-301090080.html#:~:text=(%22Innovent%22)%20(HKEX,a%20Phase%201b%20clinical%20trial%20(
https://www.prnewswire.com/news-releases/innovent-announces-the-preliminary-results-of-the-anti-ctla-4-monoclonal-antibody-ibi310-in-a-phase-1-clinical-study-301068478.html
Market Place
Share 
